12 completed, 2 terminated. 12 Phase 1, 2 Phase 2.
By phase and status
Follow PF-04958242: new trials by email Literature Review of PF-04958242 trials Research Report on PF-04958242
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
BIIB104, Placebo - Healthy Volunteers | Phase 1 | Completed | Biogen | 31 | 2019-10-02 | 2021-03-24 |
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
BIIB104, Placebo - Cognitive Impairment Associated With Schizophrenia | Phase 2 | Completed | Biogen | 195 | 2018-11-15 | 2023-04-18 |
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
PF-04958242, placebo - Cognitive Impairment Associated With Schizophrenia (CIAS) | Phase 2 | Terminated | Biogen | 35 | 2016-08-29 | 2020-01-09 |
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects
PF-04958242, Itraconazole - Healthy | Phase 1 | Completed | Biogen | 13 | 2015-02-05 | 2020-01-09 |
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
PF-04958242, Placebo - Schizophrenia | Phase 1 | Completed | Biogen | 39 | 2015-01-06 | 2021-10-25 |
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
PF-04958242, Placebo - Healthy | Phase 1 | Completed | Biogen | 12 | 2014-09-22 | 2020-01-07 |
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
PF-04958242, Ketamine, Placebo - Schizophrenia | Phase 1 | Completed | Biogen | 29 | 2012-12-01 | 2019-11-21 |
Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation
PF-04958242 capsule, PF-04958242 oral solution - Healthy | Phase 1 | Completed | Biogen | 12 | 2012-07-01 | 2019-11-21 |
A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss
PF-04958242, Placebo - Hearing Loss, Sensorineural | Phase 1 | Completed | Biogen | 44 | 2011-12-01 | 2019-11-21 |
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia
PF-04958242, Placebo - Schizophrenia | Phase 1 | Completed | Biogen | 30 | 2011-11-01 | 2019-11-21 |
A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects
Placebo, PF-04958242 - Healthy Volunteer | Phase 1 | Completed | Biogen | 112 | 2011-06-24 | 2019-12-24 |
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
PF-04958242, Placebo - Schizophrenia | Phase 1 | Completed | Biogen | 39 | 2011-06-01 | 2019-11-21 |
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers
PF-04958242, Placebo - Healthy Volunteers | Phase 1 | Terminated | Biogen | 20 | 2010-11-24 | 2019-12-24 |
First-in-Human Study of PF-04958242 in Healthy Volunteers
PF-04958242, Placebo - Healthy Volunteer | Phase 1 | Completed | Biogen | 24 | 2010-07-15 | 2019-12-24 |
Conditions studied
Schizophrenia (5) · Hearing Loss, Sensorineural (1)
Sponsors
Biogen (14)
Countries
United States (12) · Singapore (2) · Germany (1) · Japan (1) · Spain (1) · United Kingdom (1)
Results publications
PMID 25997115
NIH funding
2018 (1)